Investors

Oxford Vacmedix is currently raising Series B funds.

Seeking Investment

Series B

Oxford Vacmedix is currently raising Series B funds to take OVM-200 to Phase 2, manufacture and complete Phase 1 for OVM-100, and complete development and commercialise the AMR diagnostic test.

The Series B raise is for $20m at a valuation for Oxford Vacmedix of $54m. The lead investment in this round has already been made by OVM’s largest shareholder with an additional investment from a leading charity Prostate Cancer UK.

OVM has a successful history of investment with funds of over $14.0m invested to date including $12.5m in Series A fund.

In addition to equity investment OVM also has a strong track record of attracting non-dilutive grants. To date OVM has received or been party to grants totalling approximately $3.5m from Innovate UK, the funding organisation of the UK Government.

Licensing and partnering

The ROP platform is very broad with applications in infectious disease as well as oncology, in diagnostics as well as therapeutics and also for applications in animal health.

Some diagnostic indications have been licensed to Changzhou Biotech in China who recently announced regulatory approval in China for an ROP based diagnostic for Tuberculosis. In addition, OVM’s largest shareholder Dx&Vx of South Korea recently licenced lead vaccine OVM-200 for clinical development in S. Korea, China, and India.

The AMR test will fulfil a real need in a growing market. OVM is looking for partners to commercialise the kit.

OVM is open to licensing other diagnostic applications of the ROP technology, infectious disease applications and the use of the ROP technology for animal health, and welcomes enquiries.

OVM is also interested in collaborating with Pharmaceutical companies that can provide checkpoint inhibitors suitable for combination with ROP vaccines. In Phase 2 trials.

Diagnostic Applications

Veterinary Applications